EUVIMEDEUVIMED entdecken
Crossref

Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma

Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Sotaro Goto, Yasuhiko Yamamura, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura und 2 weitere

Annals of Hematology · 2023-06 · 102 (6) · 1485-1500

DOI: 10.1007/s00277-023-05233-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 28.04.2023. Verfasst von Yu Yagi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Frailty, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal dose intensity of chemotherapy for elderly patients with diffuse large B cell lymphoma (DLBCL) remains controversial because of concerns about adverse events and comorbidities related to the patients' frailty. This single-center study retrospectively analyzed patients aged ≥ 70 years who were newly diagnosed with DLBCL and received chemotherapy between 2004 and 2022. Survival outcomes and treatment-related mortality (TRM) were stratified according to geriatric assessment variables, and the influence of chemotherapy dose intensity on outcomes was assessed using the frailty score with a Cox hazards model with restricted cubic spline (RCS) in patients aged 70-79 years. In total, 337 patients were included. The frailty score accurately predicted prognosis (5-year overall survival [OS]: 73.1%, 60.2%, and 29.7% in fit, unfit, and frail patients, respectively; P < 0.001) and TRM (5-year TRM: 0%, 5.4%, and 16.8 in fit, unfit, and frail patients, respectively; P < 0.001). Cox regression with RCS demonstrated a linear association between dose intensity and survival outcomes. Initial dose intensity (IDI) and relative dose intensity (RDI) had a significant impact on OS in fit patients. However, IDI and RDI had no significant effect on survival in non-fit (unfit and frail) patients. The frailty score identified non-fit patients with poorer survival and a higher risk of TRM. While fit patients were likely to benefit from full-dose R-CHOP, unfit and frail patients would likely benefit more from attenuated R-CHOP. This study suggested a potential role for the frailty score in individualizing treatment intensity in elderly patients with DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtyLymphoma, Large B-Cell, DiffuseAgedHumansTreatment OutcomeRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsRituximabPrognosisCyclophosphamideDoxorubicinVincristinePrednisone

Stichwörter der Autor:innen

Charlson Comorbidity IndexDiffuse large B cell lymphomaElderly patientsFrailty scoreGeriatric Nutritional Risk Index

Substanzen

RituximabCyclophosphamideDoxorubicinVincristinePrednisone

Autor:innen und Institutionen

  • Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. yuusuke_kanemasa@tmhp.jp.
  • Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Hon-komagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Zitieren

APA

Yagi, Y., Kanemasa, Y., Sasaki, Y., Goto, S., Yamamura, Y., Ishimine, K., Hayashi, Y., Mino, M., Ohigashi, A., Morita, Y., Tamura, T., Nakamura, S., Okuya, T., & Shimoyama, T. (2023). Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma. Annals of Hematology, 102(6), 1485-1500. https://doi.org/10.1007/s00277-023-05233-2

Vancouver

Yagi Y, Kanemasa Y, Sasaki Y, Goto S, Yamamura Y, Ishimine K, et al. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma. Annals of Hematology. 2023;102(6):1485-1500. doi:10.1007/s00277-023-05233-2

BibTeX
@article{Yagi2023,
  author = {Yagi, Yu and Kanemasa, Yusuke and Sasaki, Yuki and Goto, Sotaro and Yamamura, Yasuhiko and Ishimine, Kento and Hayashi, Yudai and Mino, Mano and Ohigashi, An and Morita, Yuka and Tamura, Taichi and Nakamura, Shohei and Okuya, Toshihiro and Shimoyama, Tatsu},
  title = {Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma},
  journal = {Annals of Hematology},
  year = {2023},
  volume = {102},
  number = {6},
  pages = {1485--1500},
  doi = {10.1007/s00277-023-05233-2}
}
Kostenlos starten →